We produce institutional quality equity research on small/midcap healthcare and life sciences companies, making it available to all investors wherever they are based. Our goal is to bring exciting investment ideas to investors, and to assist companies in achieving their objectives.
10
Research Clients
310
Reports published
10k+
Readers in database
ICYMI: @arecor_plc's £6m raise will fund the strategic acquisition of @TetrisPharma & accelerate #Ogluo roll-out (a ready-to-use #glucagon auto-injector for severe hypoglycaemia in diabetics) 1/n
£20m fundraise will support ANGLE’s multi-pronged commercial strategy to establish @Parsortix #LiquidBiopsy as the leader in harvesting CTCs. This follows recent FDA clearance in #BreastCancer which should accelerate revenues. For more on $AGL see:
https://www.trinitydelta.org/companies/angle/
Trading update from #AllergyTherapeutics highlights underlying growth and continued cost control. Key clinical trials in grass & peanut #allergy remain on track to start in 2022.
For more on #AGY:
https://www.trinitydelta.org/companies/allergy-therapeutics/
Business update for @arecor_plc highlights further revenue generating partnerships expected H2 and beyond. US Phase I data for ultra-rapid #insulin #AT247 continue to be expected H2 & ultra-concentrated #AT278 is on track to start further studies later this year. #AREC $AREC
H122 results highlight @RedxPharma pipeline progress. Cash (incl recent c £34m equity raise) + modest risk-adj milestones provides runway thru end-2023, comfortably supporting Phase II plans for #RXC004 in #oncology & #RXC007 in #fibrosis. $REDX #REDX https://www.trinitydelta.org/companies/redx-pharma/
Continued momentum for ANGLE’s @Parsortix Pharma Services offering with an additional contract owing to trial progression with an existing customer. New contract is worth up to $1.2m and highlights the growth potential of this relatively nascent business opportunity. $AGL #AGL
Please sign up here to be added to our distribution database
;